Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1-positive locally advanced/metastatic NSCLC

Yazar
Penrod, J.
Dang, T.
Yin, L.
Lopes, G.
Turna, H. Z.
Mok, T. S. K.
Wu, Y-L.
Kudaba, I.
Kowalski, D. M.
Cho, B. C.
de Castro, G.
Srimuninnimit, V.
Laktionov, K. K.
Bondarenko, I.
Kubota, K.
Caglevic, C.
Karaszewska, B.
Üst veri
Tüm öğe kaydını göster
Bağlantı
http://hdl.handle.net/20.500.12627/25773
Koleksiyonlar